132
Participants
Start Date
October 31, 2012
Primary Completion Date
December 2, 2016
Study Completion Date
March 12, 2018
Atezolizumab [TECENTRIQ]
Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
Vanucizumab
Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram \[mg\] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
Cliniques Universitaires St-Luc, Brussels
UZ Leuven Gasthuisberg, Leuven
Centre Francois Baclesse; Oncologie, Caen
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid
Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona
Institut Bergonie; Oncologie, Bordeaux
ICO - Site René Gauducheau, Saint-Herblain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia
Centre Leon Berard; Departement Oncologie Medicale, Lyon
Institut Curie; Oncologie Medicale, Paris
Institut Gustave Roussy; Sitep, Villejuif
Hospital del Mar; Servicio de Oncologia, Barcelona
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona
Hoffmann-La Roche
INDUSTRY